Yüklüyor......
Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies
Monoclonal antibodies against the SARS-CoV-2 spike protein, notably, those developed by Regeneron Pharmaceuticals and Eli Lilly and Company have proven to provide protection against severe COVID-19. The emergence of SARS-CoV-2 variants with heavily mutated spike proteins raises the concern that the...
Kaydedildi:
| Yayımlandı: | bioRxiv |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Cold Spring Harbor Laboratory
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7899448/ https://ncbi.nlm.nih.gov/pubmed/33619484 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.02.18.431897 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|